000 03838nam a22004695i 4500
001 978-3-642-38404-2
003 DE-He213
005 20140220082517.0
007 cr nn 008mamaa
008 131212s2014 gw | s |||| 0|eng d
020 _a9783642384042
_9978-3-642-38404-2
024 7 _a10.1007/978-3-642-38404-2
_2doi
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
100 1 _aLübbert, Michael.
_eeditor.
245 1 0 _aEpigenetic Therapy of Cancer
_h[electronic resource] :
_bPreclinical Models and Treatment Approaches /
_cedited by Michael Lübbert, Peter A. Jones.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg :
_bImprint: Springer,
_c2014.
300 _aX, 325 p. 48 illus., 14 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aThe fundamental role of epigenetic regulation for normal and disturbed all growth and differentiation -- Mouse models to study DNA methylation in cancer research -- Epigenetic regulation of normal hematopoietic development -- Epigenetic regulation of globin genes and disturbances in hemoglobinopathies -- DNA methylation abnormalities in hematopoietic disorders: biological significance and methodological approaches -- Epigenetic modifications mediated by the AML1/ETO and MLL leukemia fusion proteins -- Epigenetic abnormalities in lung cancer -- Pharmacodynamic Responses to DNA Methyltransferase Inhibition -- Histone Methyltransferases: Opportunities in Cancer Drug Discovery -- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy -- Clinical Implications of Epigenetic Alterations in Lung Cancer -- Epigenetic disturbances in colorectal cancer -- Epigenetic Therapies in Solid Tumours: from preclinical models to clinical trial results.
520 _aThe growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors. This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.
650 0 _aMedicine.
650 0 _aGene therapy.
650 0 _aHematology.
650 0 _aOncology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOncology.
650 2 4 _aHematology.
650 2 4 _aGene Therapy.
700 1 _aJones, Peter A.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783642384035
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-38404-2
912 _aZDB-2-SME
999 _c93239
_d93239